Clinical Trials Directory

Trials / Completed

CompletedNCT03802526

Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2

Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2 in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
37 (actual)
Sponsor
NVP Healthcare · Industry
Sex
All
Age
19 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to compare the pharmacokinetics and safety/tolerability between NVP-1805-R1 and NVP-1805-R2

Detailed description

pharmacokinetics and safety/tolerability between NVP-1805-R1 and NVP-1805-R2

Conditions

Interventions

TypeNameDescription
DRUGNVP-1805-R11 tablet, multiple oral dosing
DRUGNVP-1805-R21 tablet, multiple oral dosing
DRUGNVP-1805-R1 and NVP-1805-R2NVP-1805-R1,1 tablet and NVP-1805-R2, 1 tablet, co-administration, multiple oral dosing

Timeline

Start date
2019-04-03
Primary completion
2019-07-04
Completion
2019-09-27
First posted
2019-01-14
Last updated
2019-11-29

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT03802526. Inclusion in this directory is not an endorsement.

Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2 (NCT03802526) · Clinical Trials Directory